Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/r HR MDS) Topline read-out from the Phase II BEXMAB trial confirms earlier positive findings ...

急性髓系白血病（AML）常见于老年患者，高强度化疗预后不佳。研究人员开展了低强度治疗的系统性回顾和网络荟萃分析。结果显示，AZA + VEN、LDAC + glasdegib 等方案疗效突出。该研究为老年 AML 患者治疗提供依据，意义重大。

TURKU, FI / ACCESS Newswire / April 15, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Inside Information: BEXMAB Phase II trial met its primary endpoint in treatment-resistant High Risk MDS (r/ ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac’s ...

Historically, BPDCN treatment relied on chemotherapy regimens adapted from leukemia or lymphoma protocols. However, recent breakthroughs have transformed the treatment paradigm. ELZONRIS (Stemline ...

More New Zealanders will have access to medicines for blood cancers, bowel diseases, eczema and arthritis, following Pharmac’s decision to widen access to four medicines for six health conditions from ...

Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac's decision to widen access ...

The drug-funding agency estimated that 1200 patients would benefit this year, rising to more than 5000 annually after 2030.

Investing.com — 2025年4月9日周三，科锐思 (NASDAQ: CRIS)在2025年琼斯医疗保健与技术创新会议上发表演讲。公司概述了其对IRAK4项目的战略重点，强调了在血液系统恶性肿瘤如非霍奇金淋巴瘤 (NHL)和急性髓系白血病 (AML)领域的机会。科锐思既强调了其疗法的良好潜力，也指出了患者招募和资源分配方面的挑战。

Investing.com — 2025年4月9日周三，新达制药 (Syndax Pharmaceuticals) (NASDAQ: SNDX)参加了Stifel 2025虚拟靶向肿瘤论坛。公司重点介绍了其战略计划，专注于新批准药物Nectimvo和REVUFORGE的商业化。虽然对早期需求和医生积极反馈表示乐观，但他们也承认监管变化和关税可能带来的挑战。